Viewing nowCombinationSitagliptin/Metformin XR Sustained Release Tablet 100/1000 mg
Metformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.

MFDS item code 201504896 · Approved 2015.07.16 · Insurance code 643307370
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is a combination drug containing sitagliptin and metformin, used in conjunction with dietary and exercise therapy to help improve blood sugar control in adults with type 2 diabetes. It is suitable for those who have not previously experienced diabetes medication treatment or have difficulty controlling blood sugar with a single drug. Additionally, it may be used when monotherapy with either metformin or sitagliptin is ineffective. If blood sugar control is difficult with the combination of metformin and sulfonylurea, or metformin and thiazolidinedione, this combination medication can be added. It is effective to use this combination when blood sugar control remains insufficient while using insulin and metformin. In summary, this medication is used to improve blood sugar levels in adults with type 2 diabetes who struggle to achieve adequate blood sugar control with various diabetes therapies.
For antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, take this drug with a meal once daily, preferably in the evening, and increase the dose gradually. To maintain its extended-release properties, swallow this drug whole without splitting, crushing, grinding, or chewing it. Take 1 tablet of this drug 100/1000 mg extended-release tablet once daily. Patients taking this drug 50/500 mg extended-release tablets or 50/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently receiving metformin therapy: For patients with no prior experience of antidiabetic drug treatment who have inadequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this drug is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin 2000 mg to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin therapy: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial total daily dose of this drug is sitagliptin 100 mg and the current dose of metformin. - Patients switching from concomitant sitagliptin and metformin therapy to this drug may start with their current doses of sitagliptin and metformin. - Patients who were receiving immediate-release tablets at a dose of 850 mg or 1000 mg twice daily with their current metformin regimen may start with this drug 50/1000 mg extended-release tablets at a dose of 2 tablets once daily. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this drug is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. Increase the dose gradually to reduce gastrointestinal adverse reactions caused by metformin. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have evaluated the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this drug. Any change in the treatment regimen for type 2 diabetes may result in changes in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other symptoms that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment should not be initiated with this drug, since the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because of its metformin component (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin, and is used for diabetes treatment. Though rare, it may cause serious allergic reactions; if symptoms such as hives, rash, difficulty breathing, or swelling of the face or neck occur, usage should be stopped immediately and a healthcare professional consulted. Acute pancreatitis may occur, so if symptoms such as severe abdominal pain, vomiting, or fever arise, the doctor should be notified immediately. This medication should not be administered to patients with severely decreased kidney function, heart failure, severe infections, or dehydration, and should be temporarily discontinued before and after examinations using radiocontrast agents. It is not to be administered to women who are pregnant or may become pregnant, nursing mothers, or children and adolescents under 18 years of age. As this medication is excreted through the kidneys, elderly patients or those with reduced kidney function should undergo regular kidney function tests, and dosage adjustments may be necessary. Be cautious of hypoglycemic symptoms during treatment, especially when taken together with insulin or sulfonylurea medications as the risk of hypoglycemia may increase. Due to the metformin component, lactic acidosis, a rare but potentially fatal metabolic disorder, may occur, so if severe dehydration, liver disease, cardiopulmonary disease, or excessive alcohol consumption is present, usage should be stopped immediately and medical consultation should follow. During the course of treatment, regular meals and exercise should be maintained, and regular blood sugar, kidney function, and blood tests should be conducted to monitor treatment effectiveness and side effects. Additionally, inform healthcare professionals if any other medications that may interact with this drug are being taken. In the case of surgery or severe trauma, this medication should be temporarily discontinued, and resumed only after the patient's condition stabilizes. Finally, if there are any occurrences of blisters or severe joint pain while taking this medication, consult a doctor immediately.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture; therefore, it should be stored in a tightly sealed container. Also, avoid storing in extremely hot or cold places, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius.
Bright blue, bilaterally convex, oval-shaped, sustained release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.